Remdesivir is an overpriced, sometimes harmful and mostly ineffective patented medication being promoted by liberals to treat coronavirus. It is administered intravenously and thus requires a very costly 5-day stay in a hospital, in addition to thousands of dollars per patient charged by a pharmaceutical company for the medication itself. Although remdesivir was heavily touted by liberals, on Oct. 16 CNN admitted, "Big global study finds remdesivir doesn't help Covid-19 patients."
As of November 19, 2020, "A World Health Organization panel is now recommending against the use of the antiviral remdesivir in hospitalized Covid-19 patients, saying there is no evidence that the drug — which U.S. regulators have approved for the treatment of the coronavirus — improves mortality."
Remdesivir depends on a very specific enzyme and thus might not work if its conformation is slightly changed. The overall costs, including hospital expenses, for administering remdesivir to a patient can be as high as $20,000 for a full treatment. But hospitals receive special financial incentives to administer remdesivir despite its ineffectiveness.
Some suspect that overuse of remdesivir may result in viral resistance to the drug, which is a strong reason to prefer hydroxychloroquine over remdesivir.
The Remdesivir data from the Medicare Tracking System reveals of the 7,960 beneficiaries prescribed Remdesivir for Covid-19, 2,058 died. That is 25.9%.
46% of people died within 14 days of the Remdesivir Treatment. The Remdesivir Treatment was established in U.S. Hospitals at the direction of Dr. Anthony Fauci. Serious adverse events were reported in 131 of the 532 patients who received Remdesivir. That is 24.6%.
- "CMS in October announced interim add-on payments for COVID-19 treatments including remdesivir through the HHS-declared public health emergency. The declaration next expires in January, though stakeholders think it’s likely the emergency will be renewed."